Phathom Pharmaceuticals, Inc. PHAT Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s contract liabilities?
- Phathom Pharmaceuticals, Inc. (PHAT) reported contract liabilities of $347.9M in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s contract liabilities changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s contract liabilities increased by 1.2% year-over-year, from $343.81M to $347.9M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s contract liabilities?
- Over 3 years (2022 to 2025), Phathom Pharmaceuticals, Inc.'s contract liabilities has grown at a 47.3% compound annual growth rate (CAGR), from $109.53M to $350.12M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.